Business Identifier: NO Business Identifier is currently available for this company.
Public Profile: EyeRx Research, Inc. is focused to developing and bringing to the commercial marketplace products that will aid vision and prevent blindness. There is an ever-increasing need for such products and EyeRx intends to benefit mankind by addressing that need. EyeRx has been deeply involved with the following which have significant market potential: Topical Aminocaproic Acid, CaprogelTM: Inhibition of clot dissolution improves the prognosis for traumatic hyphema. This gel product, currently licensed to ISTA Pharmaceuticals, obviates systemic toxicity. Anti-sense Oligonucelotide Allograft Anti-Rejection Pharmacology: ICAM expression is inhibited by donor tissue incubation with safe and highly specific oligonucleotide drugs. Numerous topical applications are under investigation. Topical Epithelial LASEK Solutions: This new refractive procedure has tremendous potential to avoid microkeratome complications. Our solutions can preserve epithelial integrity, thereby improving outcomes and limiting toxicity. Systemic Neuroprotective Anti-oxidants: Glaucoma and many other neuro-degenerative diseases may respond favorably to anti-oxidant therapy, particularly those that activate non-traditional, non-nutritional scavenger pathways. Permanent Radio Frequency Transmission Intra-Ocular Pressure Sensor Implants: Glaucoma therapy and pathogenesis will benefit tremendously from continuous monitoring of IOP through microscopic limbal or Seton implants. Topical Photodynamic Therapy for Ocular Neovascularization and Neoplasia: Customary laser settings produce thermal and collateral damage, which can be avoided with photosensitizers matched to appropriately coupled wavelengths. Lacritin Dry Eye Treatment: Lacritin is a recently identified component of tears which increases tear secretion and controls underlying inflamation.